PROMISING NEW DRUGS FOR THE TREATMENT OF HER2-POSITIVE BREAST CANCER


V.A. Gorbunova

Russian Oncological Scitntific Center n.a. N.N. Blokhin RAMS, Moscow
The paper presents new developments in the drug treatment of HER2- positive breast cancer, which are extremely important next stage in the medical oncology. This review presents an analysis of studies evaluating the effectiveness of therapy for breast cancer. The data of the studies comparing the efficacy, safety and pharmacokinetic parameters of subcutaneous and intravenous administration of trastuzumab are discussed. The design and methodology of a randomized, open international study EMILIA, evaluating the effectiveness of TDM-1 compared with a combination of lapatinib + capecitabine are described in detail.

About the Autors


V.A. Gorbunova – MD, Prof., Head of the Department of Chemotherapy at the Russian Oncological Scitntific Center n.a. N.N. Blokhin RAMS; e-mail: veragorbounova@mail.ru


Similar Articles


Бионика Медиа